REDWOOD City, Calif.–(Company WIRE)–Guardant Overall health, Inc. (Nasdaq: GH) right now introduced that it has achieved an agreement to settle all pending litigation about the company’s electronic sequencing technologies patents with Foundation Medicine, Inc. Pursuant to the settlement arrangement, Foundation Medication will fork out Guardant Well being $25 million as perfectly as future royalties for the remaining term of the licensed digital sequencing technological innovation patents. In convert, Guardant Wellness will grant Foundation Medicine a non-exceptional license to a defined subset of its digital sequencing technological innovation patents. As a final result of this settlement, all pending patent litigation involving Basis Medicine and Guardant Health and fitness will be dismissed.
“We are happy with the Foundation Medicine settlement agreement as it recognizes the relevance of our scientific discoveries and validates the sturdy mental property rights we have developed as a enterprise,” explained Helmy Eltoukhy, Guardant Well being Co-CEO.
About Guardant Health and fitness
Guardant Overall health is a top precision oncology enterprise concentrated on supporting conquer most cancers globally as a result of use of its proprietary exams, vast info sets and innovative analytics. The Guardant Wellness oncology system leverages abilities to travel professional adoption, increase affected person clinical results and lessen healthcare costs throughout all stages of the cancer treatment continuum. Guardant Wellness has commercially introduced Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® checks for innovative phase most cancers sufferers, and Guardant Reveal™ for early-stage cancer individuals. These exams gas development of its LUNAR screening plan, which aims to handle the needs of asymptomatic folks qualified for most cancers screening.
This push launch is made up of ahead-on the lookout statements in just the meaning of federal securities regulations, which include statements with regards to the probable utilities, values, benefits and rewards of Guardant Health’s liquid biopsy tests or assays, which involve dangers and uncertainties that could result in the genuine final results to differ materially from the predicted final results and expectations expressed in these ahead-hunting statements. These statements are centered on recent anticipations, forecasts and assumptions, and real results and success could vary materially from these statements thanks to a quantity of factors. These and additional threats and uncertainties that could influence Guardant Health’s economic and operating benefits and cause real benefits to differ materially from individuals indicated by the forward-wanting statements created in this push release contain those reviewed under the captions “Risk Factors” and “Management’s Dialogue and Examination of Financial Situation and Outcomes of Operation” and in other places in its Yearly Report on Sort 10-K for the yr ended December 31, 2020 and in its other stories submitted with the Securities and Trade Fee. The ahead-wanting statements in this press release are based on information and facts out there to Guardant Well being as of the date hereof, and Guardant Health and fitness disclaims any obligation to update any forward-wanting statements delivered to replicate any modify in its expectations or any transform in gatherings, problems, or circumstances on which any this kind of assertion is centered, besides as essential by legislation. These forward-wanting statements really should not be relied on as representing Guardant Health’s sights as of any date subsequent to the day of this press release.